Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
NCT: NCT05857969 · RECRUITING
Brief Summary
Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and genomic profiling to determine the optimal individualized therapy for cancer patients. In this study, we will enroll relapsed or refractory pediatric cancer patients with tissue available for DST and genomic profiling from the South Florida area, which is 69% Hispanic and 18% Black. Tumor cells collected from tissue taken during routine biopsy or surgery will be tested.
Frequently Asked Questions
What is Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling?
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling is a clinical trial registered under NCT05857969. Current status: RECRUITING.
What is the status of NCT05857969?
The current status of NCT05857969 (Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling) is: RECRUITING.
When did Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling start?
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling started on 2023-02-22.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.